7,568.00

-6.50

-0.09%

51,948.00

-185.00

-0.35%

28,162.25

+34.75

+0.12%

Russell 2000 Futures

2,815.20

-2.60

-0.09%

4.8940

-0.0350

-0.71%

21.15

+1.73

+8.91%

3,937.30

-32.30

-0.81%

76,797.14

-1,490.65

-1.90%

Crude Oil Dec 26

96.75

+0.29

+0.30%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqCM - Nasdaq Real Time Price USD

Nexentis Technologies Inc. (NXTS)

0.5314 -0.0539 (-9.21%)

At close: November 2 at 4:00:00 PM EST

0.5355 +0.0041 (+0.77%)

After hours: 7:42:33 PM EST

Loading Chart for NXTS

Chart Range Bar

Interval:

In partnership with ChartIQ

Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz

Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz

Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis

Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud

Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery

Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)

Nexentis Shares Rise After Solar Project Monetisation Agreement (NXTS)

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Nexentis Announces Monetization of Part of its Melz Solar Investment at $14.5 Million Project Valuation – Significant Premium to Initial Investment

Top Midday Gainers

Top Midday Gainers

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Nexentis Technologies Subsidiary MitoCareX Bio Selects Transport Protein Candidate for Drug Discovery Campaign

Mobilize your Website

View Site in Mobile | Classic

Share by: